WuXi AppTec

    OverviewSuggest Edit

    WuXi AppTec (药明康德) is a global pharmaceutical and medical device company offering an integrated end-to-end research and development services platform. The company provides its customers and partners with a broad portfolio of services, including drug discovery, pre-clinical development, and clinical processes research, as well as synthetic chemistry, biology, medicinal chemistry, analytical chemistry, toxicology, bioanalysis, and testing services. Its capabilities also include gene editing, immuno-oncology, DNA encoded library, bio-catalysis, flow chemistry, spray drying, hot melt extrusion, nanosuspension, etc.
    TypePublic
    Founded2000
    HQCN
    Websitewuxiapptec.com
    Employee Ratings2.9

    Latest Updates

    Employees (est.) (Dec 2018)17,730
    Job Openings236

    WuXi AppTec Office Locations

    WuXi AppTec has an office in
    Show all (1)

    WuXi AppTec Online and Social Media Presence

    Embed Graph

    WuXi AppTec News and Updates

    General Atlantic, WuXi AppTec lead $98m Series D in CANbridge Pharma

    Both General Atlantic and WuXi AppTec will also have the option of investing further $10 million each in the firm. The post General Atlantic, WuXi AppTec lead $98m Series D in CANbridge Pharma appeared first on DealStreetAsia.

    China Digest: JYBD raises $50m; Sequoia, WuXi AppTec back German firm

    Sequoia Capital China and WuXi AppTec have invested in German gene therapy company ViGeneron GmbH. The post China Digest: JYBD raises $50m; Sequoia, WuXi AppTec back German firm appeared first on DealStreetAsia.

    WuXi AppTec Receives 2019 Global Integrated Drug Development Competitive Strategy Innovation & Leadership Award from Frost & Sullivan

    SHANGHAI, Nov. 14, 2019 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, today announced that it received the 2019 Global Integrated Drug Development Competitive...

    WuXi AppTec Receives Investment Grade Corporate Ratings from Three Global Rating Agencies

    SHANGHAI, Nov. 6, 2019 /PRNewswire/ -- WuXi AppTec announced today that it has received investment grade corporate credit ratings from three global rating agencies: Moody's (Baa3), S&P Global Ratings (BBB-), and Fitch Ratings (BBB-); all three agencies maintain a stable outlook on WuXi...

    WuXi AppTec Reports First Half 2019 Interim Results

    Revenue Accelerated 33.7% Year-Over-Year to RMB 5,894 Million Gross Profit Up 30.0% Year-Over-Year to RMB 2,284 million[1] Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 32.0% Year-Over-Year to RMB 1,179 Million Small Molecule CDMO/CMO Pipeline has Grown to 800+...

    WuXi AppTec Named One of MIT Technology Review's 50 Smartest Companies

    SHANGHAI, June 29, 2019 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announces that it has been selected as one of MIT Technology Review's 50 Smartest Companies (TR50) for 2019. WuXi was chosen for...

    WuXi AppTec Frequently Asked Questions

    • When was WuXi AppTec founded?

      WuXi AppTec was founded in 2000.

    • How many employees does WuXi AppTec have?

      WuXi AppTec has 17,730 employees.

    • Who are WuXi AppTec competitors?

      Competitors of WuXi AppTec include Kemwell Biopharma, Noxopharm and Laurus Labs.

    • Where are WuXi AppTec offices?

      WuXi AppTec has an office in.

    • How many offices does WuXi AppTec have?

      WuXi AppTec has 1 office.